Publications
664 results found
Popat S, Smith IE, 2005, Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis., J Natl Cancer Inst, Vol: 97
Popat S, Pan H, Shao Y, et al., 2005, A prospective blinded study of microsatellite instability (MSI) as a marker of overall survival (OS) in the adjuvant treatment of colorectal cancer (CRC) patients., 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, Pages: 847S-847S, ISSN: 0732-183X
Sirohi B, Matakidou A, Ashley S, et al., 2005, Early response to platinum-based chemotherapy in non small cell lung cancer (NSCLC) predicts survival., 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, Pages: 672S-672S, ISSN: 0732-183X
Yau T, Ashley S, Popat S, et al., 2005, Case-control study comparing the cisplatin-based chemotherapy toxicity between elderly (age>/=70) and younger patient with lung cancer., 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, Pages: 680S-680S, ISSN: 0732-183X
Popat S, O'Brien M, 2005, Chemotherapy strategies in the treatment of small cell lung cancer, ANTI-CANCER DRUGS, Vol: 16, Pages: 361-372, ISSN: 0959-4973
- Author Web Link
- Cite
- Citations: 18
Popat S, Wort R, Houlston RS, 2005, Relationship between thyrnidylate synthase (TS) genotype and TS expression: A tissue microarray analysis of colorectal cancers, INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, Vol: 13, Pages: 127-133, ISSN: 1066-8969
- Author Web Link
- Cite
- Citations: 7
Popat S, Matakidou A, Houlston RS, 2005, Thymidylate synthase expression in colorectal cancer: The never-ending story - In reply, JOURNAL OF CLINICAL ONCOLOGY, Vol: 23, Pages: 2108-2109, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 1
Rini BI, Small EJ, 2005, Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma., J Clin Oncol, Vol: 23, Pages: 1028-1043, ISSN: 0732-183X
PURPOSE: To review the biology of renal cell carcinoma (RCC) leading to vascular endothelial growth factor (VEGF) overexpression and the clinical results of VEGF blockade in metastatic RCC. METHODS: A review of relevant published literature regarding VEGF, von Hippel-Lindau (VHL) gene inactivation and VEGF overexpression in RCC was performed. Further, a review of the mechanism, toxicity, and clinical development of VEGF-targeted therapy in metastatic RCC was undertaken. RESULTS: VEGF is the major proangiogenic protein that exerts a biologic effect through interaction with cellular receptors. The majority of sporadic clear-cell RCC tumors are characterized by VHL tumor suppressor gene inactivation. The resulting VHL gene silencing leads to VEGF overexpression. An antibody to VEGF (bevacizumab) has demonstrated a significant prolongation of time to disease progression compared with placebo in patients with metastatic RCC. Small molecules with inhibitory effects against the VEGF receptor have undergone initial clinical testing in metastatic RCC with substantial objective response rates. CONCLUSION: Therapeutic targeting of VEGF in RCC has strong biologic rationale and preliminary clinical efficacy. Further investigation will determine the optimal timing, sequence, and utility of these agents in RCC.
Johnson V, Volikos E, Halford SE, et al., 2005, Exon 3 β-<i>catenin</i> mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome, GUT, Vol: 54, Pages: 264-267, ISSN: 0017-5749
- Author Web Link
- Cite
- Citations: 88
Popat S, Hubner R, Houlston RS, 2005, Systematic review of microsatellite instability and colorectal cancer prognosis, JOURNAL OF CLINICAL ONCOLOGY, Vol: 23, Pages: 609-618, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 1376
Popat S, Hubner R, Houlston RS, 2004, A meta-analysis of microsatellite instability and colorectal cancer prognosis., 40th Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, Pages: 853S-853S, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 1
Popat S, Hubner R, Houlston RS, 2004, A meta-analysis of microsatellite instability and colorectal cancer prognosis., J Clin Oncol, Vol: 22
9576 Background: A number of studies have investigated the relationship between microsatellite instability (MSI) and colorectal cancer (CRC) prognosis. Although many have reported an improved overall survival with MSI, estimates of the hazard ratio (HR) between studies differ. To derive a more precise estimate of the prognostic significance of MSI, we have reviewed published studies and carried out a meta-analysis of the published literature. METHODS: Studies stratifying survival in CRC patients by MSI status were eligible for analysis. The principle outcome measure was the HR. Data from eligible studies were pooled using standard meta-analysis techniques. RESULTS: Thirty-two eligible studies reported survival in a total of 7642 cases, including 1277 with MSI. Studies varied greatly in size (median 159, range 30-1000). There was no evidence of publication bias (p>0.1, Egger's test). MSI was associated with a better prognosis. The combined HR estimate for overall survival associated with MSI was 0.65 (95% CI: 0.59-0.71, heterogeneity p=0.16, I(2)=20%). This benefit was maintained restricting analyses to clinical trial patients (HR=0.69, 95% CI: 0.56-0.85) and patients with locally advanced CRC (HR=0.67, 95% CI: 0.58-0.78). In patients treated with adjuvant 5-fluorouracil (5FU) CRCs with MSI had a better prognosis (HR=0.72, 95% CI: 0.61-0.84). While data is limited, adjuvant 5FU showed a significant benefit in tumors without MSI (HR=0.72, 95% CI: 0.57-0.92), but no benefit in tumors with MSI (HR=1.24 95% CI: 0.72-2.14). CONCLUSIONS: CRCs with MSI have at least a 15% improved survival compared to those with intact mismatch repair. Additional studies are needed to further define the benefit of adjuvant chemotherapy in locally advanced tumors with the MSI phenotype. No significant financial relationships to disclose.
Matakidou A, Hamel N, Popat S, et al., 2004, Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene, CARCINOGENESIS, Vol: 25, Pages: 369-373, ISSN: 0143-3334
- Author Web Link
- Cite
- Citations: 25
Sumpter K, Harper-Wynne C, Yeoh C, et al., 2004, Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible?, LUNG CANCER, Vol: 43, Pages: 369-370, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 5
Popat S, Matakidou A, Houlston RS, 2004, Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis, JOURNAL OF CLINICAL ONCOLOGY, Vol: 22, Pages: 529-536, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 376
Popat S, Nicholson AG, Fisher C, et al., 2004, Pulmonary masses presenting 11 years after abdominal surgery - Diagnosis: Pulmonary hyalinizing granuloma, RESPIRATION, Vol: 71, Pages: 295-297, ISSN: 0025-7931
- Author Web Link
- Cite
- Citations: 5
Popat S, Stone J, Houlston RS, 2003, Allelic imbalance in colorectal cancer at the <i>CRAC1</i> locus in early-onset colorectal cancer, CANCER GENETICS AND CYTOGENETICS, Vol: 145, Pages: 70-73, ISSN: 0165-4608
- Author Web Link
- Cite
- Citations: 8
Andreopoulou E, Ross PJ, O'Brien MER, et al., 2003, The use of MVP chemotherapy in malignant mesothelioma: Outcome and predictive factors, British Cancer Research Meeting 2003, Publisher: NATURE PUBLISHING GROUP, Pages: S22-S22, ISSN: 0007-0920
Hodgson SV, Popat S, 2003, Polymorphic sequence variants in medicine: a challenge and an opportunity, CLINICAL MEDICINE, Vol: 3, Pages: 260-264, ISSN: 1470-2118
- Author Web Link
- Cite
- Citations: 6
Popat S, Houlston RS, 2003, Inherited susceptibility to colorectal cancer., The effective management of colorectal cancer, Editors: Cunningham, Topham, Miles, London, Publisher: Aesculapius Medical Press, Pages: 3-20
Popat S, Hearle N, Bevan S, et al., 2002, Mutational analysis of <i>CD28</i> in coeliac disease, SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, Vol: 37, Pages: 536-539, ISSN: 0036-5521
Popat S, Bevan S, Braegger CP, et al., 2002, Genome screening of coeliac disease, JOURNAL OF MEDICAL GENETICS, Vol: 39, Pages: 328-331, ISSN: 0022-2593
- Author Web Link
- Cite
- Citations: 26
Popat S, Hearle N, Bevan S, et al., 2002, A genetic analysis of coeliac disease, GUT, Vol: 50, Pages: A92-A92, ISSN: 0017-5749
Popat S, Hearle N, Hogberg L, et al., 2002, Variation in the <i>CTLA4/CD28</i> gene region confers an increased risk of coeliac disease, ANNALS OF HUMAN GENETICS, Vol: 66, Pages: 125-137, ISSN: 0003-4800
- Author Web Link
- Cite
- Citations: 36
Popat S, Hearle N, Wixey J, et al., 2002, Analysis of the CTLA4 gene in Swedish coeliac disease patients, SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, Vol: 37, Pages: 28-31, ISSN: 0036-5521
- Author Web Link
- Cite
- Citations: 26
Popat S, Hogberg L, McGuire S, et al., 2001, Germline mutations in <i>TGM2</i> do not contribute to coeliac disease susceptibility in the Swedish population, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, Vol: 13, Pages: 1477-1479, ISSN: 0954-691X
- Author Web Link
- Cite
- Citations: 1
Popat S, Stone J, Coleman G, et al., 2000, Prevalence of the <i>APC</i> E1317Q variant in colorectal cancer patients, CANCER LETTERS, Vol: 149, Pages: 203-206, ISSN: 0304-3835
- Author Web Link
- Cite
- Citations: 38
Bevan S, Popat S, Houlston RS, 1999, Relative power of linkage and transmission disequilibrium test strategies to detect non-HLA linked coeliac disease susceptibility genes, GUT, Vol: 45, Pages: 668-671, ISSN: 0017-5749
- Author Web Link
- Cite
- Citations: 21
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.